Review Article Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer: A Developing Nation Perspective
|
|
- Rhoda Cummings
- 5 years ago
- Views:
Transcription
1 Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 4, December: , 2007 Review Article Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer: A Developing Nation Perspective HAMDY A. AZIM, Ph.D.* and HATEM A. AZIM Jr, MSc.** The Departments of Clinical Oncology* and Medical Oncology**, National Cancer Institute, Cairo University. ABSTRACT Background: Her-2/neu positive breast cancer is an aggressive disease with a higher potential of invasion and metastasis. It constitutes around 20% of all breast cancer cases and even a higher incidence has been reported in Egypt. Agents targeting Her-2 have been shown to be associated with improvement in response rate, disease free and overall survival. Diagnosis: Different biomarkers have recently emerged to predict the benefit of trastuzumab and/or lapatinib. Phosphatase and tensin homolog (PTEN), topoisomerase 2 alpha (TOPO2A) and p95her2 have been associated with appealing results in selecting patients who may or may not respond to these agents. Results and Conclusion: Despite the impressive results of Her-2/neu targeting agents in both the adjuvant and metastatic phases, still a significant fraction of patients are not offered these agents particularly those in countries with limited resources due to their high cost. In this review, we will discuss how we can optimally use these agents from a developing nation perspective. We will elaborate on different schedules available and will highlight the importance of incorporating different biomarkers to assist in proper selection of patients who can optimally benefit these agents. Key Words: Trastuzumab Lapatinib Her-2/neu Predictive factors Developing nations PTEN. INTRODUCTION Breast cancer is the most common malignant tumor diagnosed in women all over the world; yet its incidence differs from one region to another. In the Arab countries including Egypt, Correspondence: Dr Hatem A. Azim Jr, Department of Medical Oncology, National Cancer Institute, hatemazim@cairocure.com breast cancer constitutes around 13-35% of all female cancers [1]. The median age tend to be younger than that of the western countries with almost half of the patients diagnosed below the age of 50. Her-2/neu-postive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis [2]. This incidence is even higher in Egypt in which the incidence reaches as high as 40% in some studies [3]. In Her-2/neu positive breast cancer, Her-2 receptor is believed to be the main driving force responsible for tumor cell proliferation, metastatic potential and poor survival [2]. Accordingly, therapeutic targeting of Her-2/neu has the potential benefit to offset the signaling process initiated by the Her-2 over-expression, thus reversing the malignant features of these tumors. Currently, two drugs are approved to target the Her-2/neu gene in breast cancer; trastuzumab and lapatinib. Despite their significant activity in this setting, it has been shown that a significant proportion of patients do not derive any benefit from either agents or even both in spite of having a Her-2/neu positive tumor. Moreover, it is still unclear how to optimally use these drugs. These issues are of major importance particularly for countries with limited resources. Here, we will discuss the different schedules reported and possible mechanisms of resistance in addition to potential biomarkers that could predict response to these agents in an attempt to guide oncologists; particularly those in developing nations on how to optimize their use in breast cancer. 225
2 226 Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer TRASTUZUMAB Trastuzumab is the first agent developed to target the Her-2/neu pathway. It is a humanized monoclonal antibody that recognizes a certain epitope along the extracellular domain (ECD) of Her-2. It inhibits tumor cell growth in vitro and in vivo via 2 mechanisms. The first is downregulation of Her-2-induced nuclear signaling through inhibition of the PI3K/Akt pathway. In this aspect, trastuzumab stabilizes and activates PTEN [4], a natural inhibitor of the PI3K/Akt pathway [5], leading to accumulation of p27 kipl, which induces cell cycle arrest at the G1 phase and enhances apoptosis of tumor cells. A second mechanism is through an antibody-dependent cell-mediated cytotoxicity. In this aspect preclinical studies have shown that trastuzumab efficacy could be related to the induction of immune response against Her-2 protein [6]. Trastuzumab is used in the management of adjuvant as well as metastatic breast cancer over-expressing Her-2. In the metastatic setting, the addition of trastuzumab to chemotherapy has shown to improve all treatment endpoints [7]. In the adjuvant setting, several studies were conducted to test the role of trastuzumab in the adjuvant setting [8-11]. The results showed that the addition of trastuzumab to adjuvant chemotherapy reduces the risk of relapse by around 50% with a one third reduction in mortality; a magnitude of benefit not previously encountered by any drug in breast cancer treatment. Nevertheless, several points remain to be determined including the duration of trastuzumab in the adjuvant phase as well as its scheduling in relation to chemotherapy. The optimal duration of trastuzumab in the adjuvant setting is still unclear. Four large studies administered the drug for one year [8-10]. While this approach proved to be very effective as mentioned, still the long duration of administration is of concern given the very high cost of the drug and its potential cardiac toxicity. Trastuzumab costs around 70,000 $ for a oneyear course [12], which represents a real burden on health care systems. It also poses a significant risk of cardiac toxicity. In the Breast Cancer International Research group (BCIRG) 006 [9] and the Intergroup [10] adjuvant studies, the addition of one year of trastuzumab increased the risk of grade III and IV cardiac toxicity by 3 to 4 times compared to placebo. The FinHer study argued against the need for prolonged treatment with trastuzumab [11]. They demonstrated that adding nine weeks of this drug to chemotherapy was significantly superior to chemotherapy alone. The magnitude of benefit appeared similar to that of the one-year schedule; despite that the patients characteristics were similar. Furthermore, there was no grade III or IV cardiac toxicity encountered at all, which was reasoned by the short treatment period as well as administration of trastuzumab before anthracyclines. Thus it could be hypothesized that a short course of trastuzumab (9 weeks) could be enough to achieve the maximum benefit of the drug and thus avoiding unnecessary life threatening cardiac toxicity and inconveniently long treatment periods, which leads to significantly more added expenses. Only one study (E2198) has directly compared the 9- weeks of adjuvant trastuzumab to the one-year schedule [13]. In this study, Sledge and colleagues randomized 234 patients between the two arms. At a median follow-up period of 64 months, the five-year disease free and overall survival was equivalent in both arms. Despite that the trial was not powered to detect a difference in survival, the results remain impressive. Several clinical trials are currently ongoing by the Hellenic Oncology Research group (NCT ), NCI Paris (NCT ) and an Italian group (NCT ) to directly compare 6 versus 12 months of trastuzumab in the adjuvant setting. The timing of trastuzumab in relation to adjuvant chemotherapy remains arguable as well. Trastuzumab was given either concomitantly or sequentially after chemotherapy. In two trials [9,11], trastuzumab was given in combination with chemotherapy while in the HERA trial the drug was given sequentially following chemotherapy [8]. The Intergroup study was the only one to directly compare both approaches with clear superiority of the concomitant arm [10]. Actually in this particular study, compared to ''no trastuzumab'' arm, there was no significant benefit of trastuzumab when given following the end of chemotherapy. This was further demonstrated in the PACS-04 study [14] where patients randomised to the sequential trastuzumab arm did exactly the same like those who did not receive trastuzumab at all. This fact emphasizes the importance of the synergistic role of trastuzumab when added to chemotherapy as
3 Hamdy A. Azim & Hatem A. Azim 227 previously shown in pre-clinical models in order to enhance chemotherapy induced apoptosis. Thus, available evidence appears in favour of the concomitant application of trastuzumab with chemotherapy. The optimal chemotherapeutic regimen used in combination with trastuzumab in terms of efficacy is another issue that deserves emphasis. The BCIRG 006 study gave some important answers in this concern [9]. In this study, the addition of trastuzumab to either docetaxel/ carboplatin (TCH) or AC/docetaxel (AC TH) produced significant reduction in breast cancer relapse and mortality compared to chemotherapy alone. However subgroup analysis according to TOP2A co-amplification (30% of the whole group) has shown that the magnitude of benefit of trastuzumab in AC TH arm was similar to TCH arm when TOP2A gene was not coamplified. But, in TOPO2A positive cases, the disease free survival of all the 3 groups was exactly the same (i.e. the addition of trastuzumab didn't improve DFS in this subgroup). A systematic review of all the adjuvant studies was conducted by Slamon and colleagues [15], which further confirmed that in TOPO2A co-amplified tumors, anthracyclines alone (i.e. without trastuzumab) would probably be enough. Her-2/neu positive breast cancer has a ten times higher incidence of brain metastases compared to Her-2/neu negative tumors [16]. It has been postulated that an interaction between chemokine receptor (CXCR4) and its ligand stromal cell derived factor 1 alpha allows breast cancer cell migration through human brain microvascular endothelial cells. This interaction has been shown to be essential for development of brain metastasis [17]. As trastuzumab is a large molecule that can not cross the blood brain barrier, brain metastasis has been a devastating sanctuary site for these patients. In a previous study conducted by our group [18], 32% of patients treated with trastuzumab in the metastatic setting developed brain metastases at a median time of 14 months. This group had a median survival of 26 months which was significantly inferior to those who did not develop brain metastasis. Thus the lack of activity of trastuzumab in this setting represents a real drawback. Several biomarkers have emerged as potentially useful in predicting the response to trastuzumab. Patients who have PTEN positive tumors have been shown to derive the maximum benefit of trastuzumab compared to those with PTEN negative tumors. In a small clinical trial conducted by Nagata and colleagues, 47 patients with Her-2/neu positive breast cancer were treated with trastuzumab and paclitaxel. Those who had a high expression of PTEN had a response rate (PR and CR) around 70% compared with less than 20% for those with negative PTEN expression [19]. These results were further demonstrated by Fujita and colleagues who reported a response rate of 89% for PTEN positive tumors versus 12.5% for PTEN negative tumors (p= ) [4]. The presence of truncated receptors (p95her2) have been lately been quoted as a potential predictor marker for trastuzumab resistance. In a recently reported retrospective analysis, patients with truncated Her-2/neu had an 11% very response rate to trastuzumab-based therapy compared to 51.4% to those with tumors expressing full-length Her- 2 (p=.029) [20]. LAPATINIB Lapatinib is an oral small molecule dual inhibitor of the Her-1 and Her-2 tyrosine kinase (TK), which directly inhibits kinase activity of both receptors. Although, it blocks Her-1 and Her-2 TK with the same potency, its therapeutic benefit is only seen in breast cancer overexpressing Her-2/neu rather than Her-1 [21,22]. Lapatinib received the FDA approval in March 2007 after the impressive results shown by Geyer and colleagues in heavily pretreated Her-2/neu positive breast cancer patients [23]. In the EGF phase III trial, 321 patients with Her-2/neu positive tumors who have previously failed trastuzumab therapy were randomized to single agent capecitabine or in combination with lapatinib. In the combination arm, time to progression was almost doubled compared to capecitabine alone (p-value: 0<0.001). This was achieved without any significant increase in serious adverse events. Moreover, a recently reported trial demonstrated that patient who failed trastuzumab can achieve a considerable benefit of single agent lapatinib with a clinical benefit in the range of 25% [24]. Thus, both studies clearly confirm the absence of cross resistance between both agents.
4 228 Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer The dosing of lapatinib has recently been an area of debate. In the previously mentioned studies, lapatinib was administrated at a dose of 1500mg/day. However, a recent study has clearly shown that a similar magnitude of benefit could be achieved with a lower dose of 1,000mg/d [25]. The adoption of the lower dose would save around 1000 $ per month which would probably result in a larger number of patients, who can receive the drug particularly in countries with limited resources. Unlike trastuzumab, lapatinib is a small molecule that can cross the blood brain barrier. In the EGF pivotal study [23], patients who received lapatinib had significantly lower incidence of brain metastasis compared to those who received capecitabine alone. Moreover, in a phase II study involving patients with progressive brain metastasis following brain irradiation, lapatinib demonstrated a considerable activity with a median time to progression around 3 months [24]. Palmieri and colleagues went on to propose that lapatinib could even prevent the evolution of brain metastasis [25]. They hypothesized that lapatinib inhibits brain colonization of dual Her-1/Her-2 over-expressing breast cancer cells. Currently two large studies (ALT- TO and TEACH) are investigating the role of lapatinib in the adjuvant phase and its effect on reducing the incidence of brain metastasis. Another unique difference between lapatinib and trastuzumab is their effect on the heart. Trastuzumab have been shown to be associated with considerable cardiotoxicity particularly in the presence of doxorubicin [7]. This is obviously not the case with lapatinib. In a unique work by Perez and colleagues, they analyzed the cardiac safety of lapatinib in more than 3500 patients enrolled in clinical trials [26]. In this large analysis, only 1.6% of cases developed a cardiac adverse event; which were mostly asymptomatic, with reversible decrease in left ventricular ejection fraction occurring at similar rates in patients who were and were not pretreated with anthracyclines or trastuzumab. Little is known regarding how to predict response to lapatinib. Patients with truncated Her-2/neu (i.e. no ECD) are likely to benefit lapatinib rather than trastuzumab. Preclinical models have shown that tumors expressing p95her2 are resistant to trastuzumab but not lapatinib [20]. Recently, Cameron and colleagues have shown that resistance to lapatinib is not related to expression of p95her2 [29]. Moreover, the antitumor effects of lapatinib on Her- 2/neu-overexpressing breast cancer cells appear to be closely linked to the down-regulation of survivin [30]. Although inhibition of Her-2 autophosphorylation and signaling via MAPK and PI3K/Akt pathways may be necessary for clinical response to lapatinib, yet, it is not sufficient [21]. In this context, Gomez and colleagues have recently failed to demonstrate any correlation between response to single agent lapatinib and PTEN expression [25]. CONCLUSIONS Trastuzumab and lapatinib, while their discovery represents a milestone in treating Her- 2/neu positive breast cancer, it is obvious that still a significant proportion of patients will not derive any benefit despite over-expressing Her- 2. Moreover, the lack of cross resistance could hypothesize that certain patients will derive a benefit from one drug rather than the other. In nations with limited economy like Egypt, offering adjuvant trastuzumab remains a challenge, yet the FinHer model could serve as a more feasible approach. It is still unknown whether longer duration of trastuzumab is really needed pending the results of the 2-year trastuzumab in the HERA study. If the results turned out to be negative, we believe that there will be more interest in exploring shorter schedules of adjuvant trastuzumab. The direct comparison in the E2198 study is reassuring acknowledging the limited sample size of the study. Based on the data that have been discussed, patients with co-amplification of TOPO2A, expression of p95her2, or negative PTEN seems to derive less benefit of trastuzumab and identifying these patients seems essential especially when resources are scarce. In cases of brain metastasis, lapatinib could serve as a better alternative. Offering lapatinib in a dose of 1,000mg/d seems more rationale given the absence of strong evidence to favor the higher dose. In the era of targeted agents, better understanding of the molecular biology of different tumors could indeed guide oncologists on how to select the patients who would likely to benefit these effective; yet very expensive medications.
5 Hamdy A. Azim & Hatem A. Azim 229 A problem remains in the absence of a standardized method for assaying these biomarkers and in our opinion, this is desperately required. We are in urgent need for incorporating these different biomarkers in large scale studies to validate their predictive value on prospective basis. REFERENCES 1- El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: A literature and registry analysis. Int J Surg 2007, 5: Azim H, Azim HA Jr. Targeting Her-2/neu in breast cancer: as easy as this! Oncology. 2008, 74: El-A Helal T, Khalifa A, Kamel AS. Immunohistochemical expression of p53 and c-erbb2 proteins in breast cancer in Egypt. Anticancer Res. 2000, 20: Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006, 94: Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000, 1000: Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an antiangiogenic cocktail. Nature. 2002, 416: Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: Piccart-Gebhart MJ, Procter M, Leyland-Jones, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353: Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast cancer Res Treat. 2005, 94 (Suppl 1): S5a. 10- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Eng J Med. 2005, 353: Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant Docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006, 354: Fleck LM. The costs of caring: Who pays? Who profits? Who panders? Hastings Cent Rep. 2006, 36: Sledge GW, O'Neill A, Thor A, Kahanic SP, Zander PJ, Davidson N. Adjuvant trastuzumab: Long-term results of E2198. Poster presentation 2075, SABCS Spielmann M, Roché H, Humblet Y, Delozier T, Bourgeois H, Serin D, et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: Results of the PACS-04 trial. Poster presentation 72, SABCS Slamon DJ, Mackey J, Robert N, Crown J, Martin M, Eiremann W, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses by molecular subtypes of the disease. Poster presentation 13. SABCS Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbb-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor longterm survival in breast cancer. Int J Cancer. 1991, 49: Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res. 2004, 2: Azim HA, Azim HA Jr, Kamal NS, Tawab RA, Monem DA. A retrospective analysis on the incidence and pattern of CNS metastases among women with metastatic breast cancer over-expressing HER-2/neu receiving trastuzumab-based therapy. Poster presentation 4, NEMROCK Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004, 6: Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95her2, a truncated for of the HER2 receptor and response to anti-her2 therapies in breast cancer. J Natl Cancer Inst. 2007, 99: Spector NL, Xia W, Burris H 3 rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinase, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005, 11: Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66: Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med. 2007, 233: Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, et al. Single-agent
6 230 Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or secondline trastuzumab-containing regimens. Ann Oncol. 2009, E-pub ahead of print. 25- Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as firstline therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008, 26: Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II of lapatinib for brain metastasis in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008, 26: Gril B, Palmieri D, Bronder JL, Herring JM, Vega- Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008, 100: Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008, 83: Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008, 112: Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, et al. Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006, 66:
Treatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationBIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium
Emerging trends and recommendations BIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium Joseph Ragaz, MD, FRCPC Top-line summary Here, Oncology Exchange presents
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast cancer Chemotherapy Taxane Trastuzumab Ki-67
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Early-Stage Breast Cancer: Clinical Update Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationOutcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer
DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationBreast Cancer. Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Outcome of Patients with HER2-Positive Advanced
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationKey Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine
The Oncologist Regulatory Issues FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 QIN RYAN, AMNA IBRAHIM, MARTIN
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationBreast Cancer: the interplay of biology, drugs, radiation. Prof. L. Livi Università degli Studi di Firenze. Brescia, October 3rd 4th, 2013
Breast Cancer: the interplay of biology, drugs, radiation Prof. L. Livi Università degli Studi di Firenze Brescia, October 3rd 4th, 2013 BACKGROUND (1) The complex interactions between tumor-specific signaling
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationResearch Progress in the Use of Drugs for Breast Cancer Targeted Therapy
320 Chin J Clin Oncol (2008) 5: 320~325 DOI 10.1007/s11805-008-0320-z Research Progress in the Use of Drugs for Breast Cancer Targeted Therapy Shun e Yang Bing Zhao Department of Medical Oncology, Tumor
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationevidence watch landmarks A review and assessment of recent clinical trial data Follicular non-hodgkin lymphoma Latest research profiles
Latest research profiles evidence watch A review and assessment of recent clinical trial data Oncology Exchange provides overviews of important clinical trial data presented at the 49 th Annual Meeting
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationTargeted Therapies in HER2-Positive Breast Cancer a Systematic Review
Review Article DOI: 10.1159/000431029 Published online: June 18, 2015 Targeted Therapies in HER2-Positive Breast Cancer a Systematic Review Amelie Schramm Nikolaus De Gregorio Peter Widschwendter Visnja
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationHerceptin Pivotal Studies
Herceptin Pivotal Studies Nuhad K Ibrahim, MD, FACP Associate Professor of Medicine Breast Medical Oncology Department MD Anderson Cancer Center Houston, TX, USAE-mail: nibrahim@mdanderson.org Herceptin
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationIvyspring International Publisher INTRODUCTION. Journal of Cancer 2013, Vol. 4. Abstract
679 Ivyspring International Publisher Research Paper Journal of Cancer 2013; 4(8): 679-685. doi: 10.7150/jca.6775 Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationA Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer
A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer Kelly Khai Li Yap, MD, Debu Tripathy, MD Abstract Small node negative breast cancers measuring less than 1 cm (pt1a/bn0) are generally
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationShould trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
Breast Cancer Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer? Filippo Montemurro Unit of Investigative Clinical Oncology, Division
More informationRetrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+
Original research Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer Tiina Moilanen, 1,2 Susanna Mustanoja, 1,2 Peeter Karihtala,
More informationAnnals of Breast Cancer. MedDocs Publishers. Open Access Research Article. Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4 ; Gupta RK 2,3
Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationLet s start first reviewing the clinical and pathological features of IBC.
Welcome to this educational event sponsored by [The University of Texas] MD Anderson Cancer Center, entitled Inflammatory Breast Cancer: Biological Features. I am Massimo Cristofanilli. I m a Professor
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationKey Words. Trastuzumab Adjuvant chemotherapy Breast cancer HER-2 Systematic review Meta-analysis
The Oncologist Breast Cancer Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ISSA J. DAHABREH, a,b HELEN LINARDOU,
More informationReview Article Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
Chemotherapy Research and Practice Volume 2011, Article ID 730360, 12 pages doi:10.1155/2011/730360 Review Article Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer Toru Mukohara Department
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationAnthracycline trastuzumab regimens for HER2/neuoverexpressing breast cancer: current experience and future strategies
Annals of Oncology 19: 1530 1539, 2008 doi:10.1093/annonc/mdn292 Published online 13 May 2008 Anthracycline trastuzumab regimens for HER2/neuoverexpressing breast cancer: current experience and future
More informationThe absolute benefit from chemotherapy for both older and younger patients appeared most significant in ER-negative populations.
Hello, my name is Diane Hecht, and I am a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. It s my pleasure to talk to you today about the role of chemotherapy in this
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationManagement of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
Review Article Jpn J Clin Oncol 2010;40(11)999 1013 doi:10.1093/jjco/hyq084 Advance Access Publication 11 June 2010 Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationClinical Study Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
Oncology Volume 2012, Article ID 198412, 6 pages doi:10.1155/2012/198412 Clinical Study Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationUpdate on HER2-Positive Adjuvant Therapy
UPDTE ON HER2-POSITIVE DJUVNT THERPY Update on HER2-Positive djuvant Therapy Reshma Mahtani, DO; na Sandoval, MD; and Mohammad Jahanzeb, MD bstract HER2-positive breast cancer accounts for 15% to 2% of
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationAppendix Four. Clinical effectiveness. Contents
Appendix Four. Clinical effectiveness Contents 1. Treatment regimens and available trial data... 1 Treatment regimes in randomised controlled trials... 1 Trial outcomes as reported... 10 2. Increasing
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationREVIEW ARTICLE Trastuzumab cardiotoxicity: from clinical trials to experimental studies
British Journal of Pharmacology British Journal of Pharmacology (2017) 174 3727 3748 3727 Themed Section: New Insights into Cardiotoxicity Caused by Chemotherapeutic Agents REVIEW ARTICLE Trastuzumab cardiotoxicity:
More informationPublished Ahead of Print on January 15, 2009 as /theoncologist
The Oncologist Breast Cancer Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations MIGUEL MARTÍN, a FRANCISCO J. ESTEVA, b EMILIO ALBA, c BIJOY
More informationImportance of confirming HER2 overexpression of recurrence lesion in breast cancer patients
Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto
More informationClinical Study The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
Hindawi Analytical Cellular Pathology Volume 2017, Article ID 1350618, 5 pages https://doi.org/10.1155/2017/1350618 Clinical Study The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced
More information